Health-Related Quality of Life and Physical Activity in Children with Inherited Cardiac Arrhythmia or Inherited Cardiomyopathies: The Prospective Multicentre Controlled QUALIMYORYTHM Study Rationale, Design and Methods.

Background: Advances in paediatric cardiology has improved the prognosis of children with inherited cardiac disorders. However, health-related quality of life (QoL) and physical activity have been scarcely analysed in children with inherited cardiac arrhythmia or inherited cardiomyopathies. Moreover, current guidelines on the eligibility of young athletes with inherited cardiac disorders for sports participation mainly rely on expert opinions and remain controversial. Methods: The QUALIMYORYTHM trial is a multicentre observational controlled study. The main objective is to compare the QoL of children aged 6 to 18 years old with inherited cardiac arrhythmia (long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, or arrhythmogenic right ventricular dysplasia), or inherited cardiomyopathies (hypertrophic, dilated, or restrictive cardiomyopathy), to that of age and gender-matched healthy subjects. The secondary objective is to assess their QoL according to the disease’s clinical and genetic characteristics, the level of physical activity and motivation for sports, the exercise capacity, and the socio-demographic data. Participants will wear a tness tracker (ActiGraph GT3X accelerometer) for 2 weeks. A total of 214 children are required to observe a signicant difference of 7 ± 15 points in the PedsQL, with a power of 90% and an alpha risk of 5%. Discussion: After focusing on the survival in children with inherited cardiac disorders, current research is expanding to patient-reported outcomes and secondary prevention. The QUALIMYORYTHM trial intends to improve the level of evidence for future guidelines on sports eligibility in this population. Trial registration:


Background
Prognosis of children with congenital cardiac disorders has signi cantly improved in the past two decades, due to great advances in prenatal screening, intensive neonatal care and modern invasive therapies [1]. As a result, more attention has been recently given to health-related quality of life (QoL) and secondary prevention in paediatric cardiology [2,3].
Traditionally, congenital cardiac disorders are divided into 3 groups: congenital heart disease (CHD) for structural cardiac anomalies, inherited cardiac arrhythmia and inherited cardiomyopathies. So far, QoL studies in paediatric cardiology have mainly focused on the group of children with CHD and, although the overall level of QoL is good in this population, our group highlighted the existing correlation between exercise capacity and QoL, and the risk for physical deconditioning, even for non-serious CHD [4,5]. Indeed, despite the promotion of physical activity in the current guidelines [6-8], many children with CHD experience social barriers to physical activity and "remain on the side-line" at school or in their social life [9]. Ultimately, these patients may be exposed to the consequences of a sedentary lifestyle: overweight, high blood pressure, social exclusion, and impaired QoL [10][11][12]. Conversely, patients with CHD who have been physically active since childhood are less likely to become sedentary adults [13].
Such consistent data are not available in the literature for children from the two other groups, e.g.
inherited cardiac arrhythmia or inherited cardiomyopathies, for which QoL and physical activity have been rarely studied. Some heterogeneous data were provided from small paediatric [14][15][16] or adult [17,18] cohorts, however no prospective controlled study has analysed the determinants of QoL and the level of physical activity in children with inherited cardiac disorders [19].
The multicentre observational controlled QUALIMYORYTHM trial aims to evaluate the QoL, exercise capacity, and the level of physical activity of children with inherited cardiac arrhythmia or inherited cardiomyopathies, in comparison with a matched control population. This study will also evaluate the main factors associated with QoL in this population.

Objectives
The main objective of the QUALIMYORYTHM trial is to compare the QoL of children aged 6 to 18 years old with inherited cardiac arrhythmia or inherited cardiomyopathies to that of matched healthy children.
The secondary objective is to assess, in this population, the QoL according to the disease clinical and genetic characteristics, the level of physical activity, the exercise capacity, and the socio-demographic data.

Study design
The QUALIMYORYTHM trial is a prospective, multicentre controlled observational study with 1-month follow-up and 18-month recruitment duration. All screened subjects will be identi able throughout the study by a unique subject number. The eligible patients will be divided into 2 groups ( Fig. 1): Group 1: children aged 6 to 18 years old with an inherited cardiac arrhythmia or an inherited cardiomyopathy.
Group 2: age and gender-matched control group, with healthy children aged 6 to 18 years old.

Setting
Patients will be recruited during a paediatric cardiology consultation among the French expert centres for inherited cardiac arrhythmia or an inherited cardiomyopathies (CARDIOGEN national network, http://www. liere-cardiogen.fr). Overall, 7 university hospitals, labelled as expert centres in paediatric inherited cardiac disorders by health authorities, will be in charge of patient recruitment.
Conduct of the study will be led by the principal investigator (supported, when necessary, by the coinvestigators), a research fellow, and a clinical research coordinator, all of whom are trained in Good Clinical Practice and in the requirements of the study protocol.

Study population
Children aged of 6 to 18 years old with an inherited cardiac arrhythmia (long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, or arrhythmogenic right ventricular dysplasia), or those with an inherited cardiomyopathy (hypertrophic, dilated, or restrictive cardiomyopathy), will be prospectively recruited during their annual follow-up.
The age-and gender-matched control group will be de ned using the same method as in our previous paediatric exercise test studies [4,5,[20][21][22]. Children aged 6 to 18 years old referred to the paediatric cardiology consultation for a non-severe functional symptom linked to exercise (murmur, palpitation, or dyspnoea) or for a medical sports certi cate will be assessed for eligibility. These children will be classi ed in the control group only after a completely normal check-up, including physical examination, electrocardiogram, and echocardiography. Children with any chronic disease, medical condition (cardiac, neurologic, respiratory, muscular, or renal), or medical treatment and those requiring any further specialized medical consultation will not be eligible.
Patients who are not able to answer the quality of life questionnaire (e.g. non-French speakers, severe mental illness) will not be eligible for the study. Detailed inclusion and exclusion criteria are reported in Table 1. Table 1 Trial entry.

Inclusion criteria
• Male or female aged 6 to 18 years old.
• Group 2: Children with a completely normal check-up, referred to the paediatric cardiology consultation for a non-severe functional symptom linked to exercise (murmur, palpitation, or dyspnoea) or for a medical sports certi cate.
• Informed consent of parents or legal guardians, and oral assent of children.
Exclusion criteria • Patients who are not able to understand or ll out the questionnaires (QoL, physical activity and motivation questionnaires).
• Absolute contraindications for CPET: fever, uncontrolled asthma, respiratory failure, acute myocarditis or pericarditis, uncontrolled arrhythmias causing symptoms or haemodynamic compromise, uncontrolled heart failure, acute pulmonary embolus or pulmonary infarction, and children with mental impairment leading to inability to cooperate.
• Group 2: Children with any chronic disease, medical condition (cardiac, neurologic, respiratory, muscular, or renal), or medical treatment and those requiring any further specialized medical consultation.

Primary outcome
The primary outcome is the total QoL score with the self-reported PedsQL questionnaire. The PedsQL questionnaire has four multidimensional scales: physical functioning (8 items), emotional functioning (5 items), social functioning (5 items), and school functioning (5 items). The three summary scores are: total scale score (23 items), physical health summary score (8 items), psychosocial health summary score (15 items). Each item uses a 5-point Likert scale from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale, higher scores indicating a better QoL. This instrument was validated by Varni et al. in healthy and patient populations and its psychometric properties showed reliability, validity and responsiveness to clinical change over time [28]. The translation and cultural adaptation into French was performed by MAPI Research Institute (www.mapi-trust.org), following the international guidelines [28] and this version showed good psychometric properties [29]. Our group recently performed the complete psychometric validation of the French self and proxy versions of the PedsQL generic questionnaire for 8 to 12 year-old children [30]. We also found a good sensitivity of the PedsQL in several controlled prospective HRQoL studies among healthy controls and children with various chronic diseases [24][25][26][27].

Secondary outcomes
The level of physical activity will be assessed by: The metabolic equivalent of task (MET), measured by a tness tracker (ActiGraph GT3X accelerometer, Pensacola, FL, USA) [31]. The MET is de ned as the ratio of physical activity to basal metabolic demand. The metabolic equivalence scale ranges from 0.9 MET (at rest) to 18 MET (run at 17.5 km/h). The participants will be instructed to wear the tness tracker at the waist at all times for 14 days, except during sleep and water-based activities such as swimming or bathing. The Ricci and Gagnon physical activity questionnaire, composed by 8 items (total score < 16 points: no activity; 17 to 32 points: moderate activity; 33 to 40 points: intensive activity) [32]. The EMAPS questionnaire (motivation scale for physical activity in a health context), a 18-item motivation scale towards health-oriented physical activity recently validated in French [33].
The exercise capacity will be assessed by a cardio-pulmonary exercise test (CPET), using the same methodology as in our previous paediatric CPET studies [5,20,21][34]. The following variables will be measured: maximum oxygen uptake (VO2 max ); ventilatory anaerobic threshold (VAT); ventilatory e ciency (VE/VCO2 slope), oxygen uptake e ciency slope (OUES), and maximum oxygen pulse (VO2 max /maximum heart rate). Exercise test procedures in all participating laboratories will be harmonized before the start of the study. All centres will use the same CPET cycle ergometer protocol, to obtain a homogeneous incremental overall duration between 8 to 12 minutes: a 1-minute rest; a 3-minute warm-up (10 to 20 watts) in increments of 10, 15, or 20 watts each minute; a pedalling rate of 60 to 80 revolutions per minute; a 3-minute active recovery (20 watts); and a 2minute rest. The CPET will be considered as maximal when 3 out of the 4 following criteria will be reached: respiratory exchange ratio (RER = VCO2/VO2) ≥ 1, maximum heart rate > 85% of maximal age-predicted heart rate, limit of the patient's tolerance despite verbal encouragement, plateau of VO2 (VO2 max ) despite the increasing exercise intensity, and patient's inability to provide a minimum pedalling frequency of 60 per minute despite verbal encouragement. The VAT will be estimated using Beaver's method [35]. VO2 max and VAT values will be normalized in a percentage of the predicted VO2 max using reference values for cycle ergometer test in the general paediatric population [36,37].
When the VO2 max does not reach criteria for maximal effort, the peak VO2 will be informed, as usual in paediatrics [38, 39].
The clinical outcomes: age at diagnosis (prenatal, postnatal), genetic anomaly, NYHA functional class, blood pressure, body mass index (BMI), healthcare usage (primary and secondary care contacts, hospitalisation), pacemaker, implantable cardioverter de brillator (ICD), cardiac surgery, and medication. The socio-economic status of the patient's family.
The safety outcomes.

Page 8/16
All outcomes are reported in Table 2. Table 2 Outcome measures.

Primary outcome
• Health-related quality of life score: PedsQL self-questionnaire (versions 5-7 years and 8-12 years for children and version 13-18 years for adolescents). o Maximum oxygen pulse (VO2 max /maximum heart rate).
• Health-related quality of life score: PedsQL proxy questionnaire (versions 5-7 years and 8-12 years for children and version 13-18 years for adolescents).
• The socio-economic status of the family.

Sample size
We aim to recruit a total of 214 children in both groups. The primary outcome is the difference in the selfreported QoL score with the PedsQL instrument between the children with inherited cardiac disorders and the control group. We used the results from our previous QoL cross-sectional studies in patients with CHD to calculate the sample size [4,21,[23][24][25][26][27]. In our experience, as well as in similar studies using patient related outcomes, a difference of less than 5 points is not clinically relevant, and a difference of more than 10 points is ideal, but rarely achieved [2,25,27]. Therefore, we hypothesized to observe a difference in the total QoL score of 7 ± 15 points (over 100). With a 90% power, a bilateral alpha risk of 5%, and potentially 10% of loss to follow-up or missing data on the primary outcome, we need to include 107 patients in the group 1 and 107 patients in the group 2.

Statistical analysis
Patients' characteristics will be presented using mean and standard deviation for continuous variables, and frequencies and proportions for qualitative variables. QoL scores will be calculated with the parametric Student's t test when the distribution was Gaussian and with the Mann-Whitney test otherwise.
Association between QoL scores and physical activity, clinical and socio-demographic data will be studied using Pearson's or Spearman's coe cient. The statistical signi cance will be set at 0.05 and analyses will be performed using Statistical Analysis Systems version 9 (SAS Institute, Cary, NC, USA). Data will be managed by the clinical research unit of Montpellier University Hospital, France, in collaboration with the paediatric and congenital cardiology department.

Ethics
The study will be conducted in compliance with the Good Clinical Practices protocol and Declaration of Helsinki principles. It was approved by a drawn national Ethics Committee (CPP Sud-Est VI, 2020-A00411-38). Informed consent will be obtained from all parents or legal guardians, and oral assent will be obtained from all children. The study was registered on Clinicaltrials.gov (NCT04712136).

Expected Results And Perspectives
In the continuity of our research program on QoL and physical activity in paediatric and congenital cardiology [4,[21][22][23][24][24][25][26][27], the QUALIMYOTYRHM trial should provide, for the rst time, reliable data on health-related QoL and physical activity in children with inherited cardiac arrhythmia or inherited cardiomyopathies. From our perspective, considering the QoL as the main outcome of this trial is both original and primordial in this young population with cardiac inherited disorders. Indeed, measuring patient-reported outcomes (PRO) in paediatric cardiology should become a priority, considering that many young cardiac patients experience a low level of physical impairment during childhood, but an increased cardio-vascular risk during adulthood [2,3] [40]. This is also in line with the European Medicines Agency (EMA) promotion of PRO measures in clinical research, and more and more drug trials, even in paediatrics, currently evaluate the quality of life as a secondary outcome [41]. Moreover, our results will contribute to provide consistent baseline clinical and QoL data for future interventional clinical trials in children with inherited cardiac arrhythmia or inherited cardiomyopathies.
The QUALIMYORYTHM trial also seeks to determine the level of physical activity in the contemporary generation of children with inherited cardiac disorders, using modern connected technology adapted to this population, such as tness trackers. In the absence of any reliable risk strati cation in those children, the current guidelines on eligibility of young athletes with inherited cardiac disorders for sports participation mainly rely on expert opinions [42][43][44][45], and conclusions by the experts have classically not been the same on both sides of the Atlantic [46]. The difference commonly made between recreational and competitive sport is probably more about medico-legal issues for the practitioner, than for the patient's own interest. For example, more than a decade ago, the European guidelines for competitive sport participation in the long QT syndrome were very restrictive [43]. Yet, in a recent study from a cohort of 172 appropriately managed children with long QT syndrome, cardiac event rates were low and occurred during recreational, but not competitive activities [47]. Similarly, in a cohort of 129 young athletes with ICD, most of them having a long QT syndrome or a hypertrophic cardiomyopathy, and participating in competitive or dangerous sports, there were no occurrences of death, arrest, or injury related to arrhythmia, during sports; interestingly, this study found that 27% patients received at least one shock, only 4 during sports, which is similar to unselected non-athletic paediatric ICD cohorts [48]. Based on convergent studies reporting a low risk of cardiac event in athletes with optimal treatment for long QT syndrome [47][48][49][50], a progressive trend towards a different medical approach has been observed, involving the patient-athlete in shared decision-making. Therefore, the 2015 US guidelines [51] have been less restrictive regarding high intensity recreational exercise and competitive sports, especially for asymptomatic genotype-positive/phenotype-negative athletes. More recently, the 2020 European guidelines have moved on step further in promoting supervised and regular physical activity in patients with inherited cardiac disorders [45].
Nevertheless, most published studies are retrospective and have not evaluated sports with the highest cardiovascular demand (only a few class IIIB and IIIC sports), or recreational sports in children with the rarest or most serious inherited cardiac disorders. Indeed, in their recent review, Masrur et al. concluded that there are insu cient data on the risks of exercise in Brugada syndrome to make recommendations for exercise [52]. Therefore, the QUALIMYORYTHM trial should contribute to precise how the recommendations are currently applied "in the real life", and measure their potential impact on QoL and physical activity of children with inherited cardiac arrhythmia or inherited cardiomyopathies. Furthermore, the QUALIMYORYTHM trial will provide, for the rst time in a population of children with inherited cardiac disorders, consistent cardiopulmonary tness data, such as the maximum oxygen uptake (VO2 max ), the anaerobic threshold, the ventilatory e ciency, and the exercise stroke volume.
Moreover, this study will also bring original information about the level of motivation of children with inherited cardiac disorders for physical activity, and its degree of correlation with the actual levels of physical activity and exercise capacity. In paediatric cardiology, cardiopulmonary tness has mainly been determined in children with CHD [5,53], but these results cannot be easily transposed to inherited cardiac disorders, as the underlying pathophysiology and haemodynamic consequences are different. For instance, animal models have demonstrated that the bene cial effects of training on the heart effects of training are related to the signalling pathways of myocardial hypertrophy and brosis, but such ndings need to be further analysed in patients with inherited cardiomyopathies [54].
If the QUALIMYORYTHM trial nds that physical activity and exercise capacity in children with inherited cardiac arrhythmia or inherited cardiomyopathies are similar to those of healthy children, without any additional risk, the level of evidence for future guidelines on sports eligibility in this population will be signi cantly improved. Conversely, if physical activity and exercise capacity in children with inherited cardiac disorders are signi cantly impaired, it will open a new research eld on rehabilitation programs in this population. Indeed, if physical deconditioning is diagnosed and managed at an early stage in patients with inherited cardiac disorders, participation in rehabilitation programs could reverse the vicious circle of deconditioning, and, ultimately participate in reducing the cardio-vascular risks related to inactivity, as it has been suggested in CHD [22,[55][56][57], as well as in many chronic diseases [ The study will be conducted in compliance with the Good Clinical Practices protocol and Declaration of Helsinki principles. It was approved by a drawn national Ethics Committee (CPP Sud-Est VI, 2020-A00411-38) and was registered on Clinicaltrials.gov (NCT04712136). Informed consent will be obtained from all parents or legal guardians, and oral assent will be obtained from all children.

Consent for publication
This study does not contain data from any individual person (images or videos).

Availability of data and material
Not applicable.

Competing interests
The Authors declare that they have no con ict of interest.